Possible to Reduce Treatment Burden in HER2-Positive Breast Cancer?

March 1, 2017
Sara M. Tolaney, MD, MPH

This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer.

In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses the idea of using clinical features to reduce treatment burden in patients with HER2-positive breast cancer.

While biomarkers that could help clinicians more appropriately personalize treatments for patients with HER2-positive disease are still in development, trials using clinical features have already explored different ways to reduce treatment toxicity.

Tolaney discusses one such trial, the APT (Adjuvant Paclitaxel and Trastuzumab) trial, which examined a less toxic regimen for patients with small HER2-positive tumors: 12 weeks of weekly paclitaxel (80 mg/m2) plus weekly trastuzumab (2 mg/kg), followed by 9 months of trastuzumab (6 mg/kg) every 3 weeks.

Related Content:

News